Two other corporate venturing units have joined drugs company GlaxoSmithkline’s (GSK) SR One unit in the $35m series B round for Genocea Biosciences, a US-based vaccine development company.
Johnson & Johnson Development Corporation, which invests on behalf of medical device company Johnson & Johnson, and MP Healthcare Venture Management, a jointly owned subsidiary of Mitsubishi Tanabe Pharma and its parent company, Mitsubishi Chemical, were Genocea’s two new investors.
Alongside venture capital firm Skyline Ventures as the third new investor, were GSK’s SR One, and venture capital firms Auriga Partners, Cycad Group, and Alexandria Real Estate Equities, Lux Capital Management, Polaris Venture Partners and Morningside Ventures.
In February 2009, Genocea raised a $23m series A round led by Lux and Polaris, which had provided initial, undisclosed funding to Genocea in December 2006.